All terms in DRUGBANK

Label Id Description
Deflazacort DB11921 [Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.[A179449] Deflazacort delays the onset of muscle related complications resulting from DMD[A179455], prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]]
Lesogaberan DB11920 [Lesogaberan has been used in trials studying the treatment and basic science of GERD, Reflux, Heartburn, Regurgitation, and Reflux Disease, among others.]
Tesidolumab DB11926 [Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.]
Vistusertib DB11925 [Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma.]
Safingol DB11924 [Safingol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.]
Decoglurant DB11923 [Decoglurant has been used in trials studying the treatment of Major Depressive Disorder.]
6-O-benzylguanine DB11919 [6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.]
Guadecitabine DB11918 [Guadecitabine is under investigation for the treatment of Previously Treated Metastatic Colorectal Cancer.]
Vatiquinone DB11917 [Vatiquinone has been investigated for the treatment and prevention of Retinopathy, Rett Syndrome, Genetic Disease, Noise-induced Hearing Loss, and Methylmalonic Aciduria and Homocystinuria,Cblc Type.]
Indium In-111 DB11916 [Indium In-111 is under investigation in clinical trial NCT00493454 (Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas).]
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated) DB10602 [A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.]
Riboprine DB11933 [Ipa has been used in trials studying the treatment of Nausea and Surgical Site Infection.]
Abametapir DB11932 [Abametapir has been investigated in Pediculosis.]
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated) DB10601 [A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.]
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) DB10600 [A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.]
Varlilumab DB11930 [Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.]
Sus scrofa skin DB10606 [Sus scrofa skin or pelt is used in allergenic testing.]
Kynurenic Acid DB11937 [Kynurenic Acid is under investigation in clinical trial NCT02340325 (FS2 Safety and Tolerability Study in Healthy Volunteers).]
Bempedoic acid DB11936 [Bempedoic acid has been used in trials studying the treatment of Hypertension, Dyslipidemia, Hyperlipidemia, Type 2 Diabetes, and Hypercholesterolemia, among others.]
Mesocricetus auratus skin DB10605 [Mesocricetus auratus skin or pelt is used in allergenic testing.]